Evidence map›Paper›PMID 39589413›Full record

ArticleImmunogenetics2024

Exploring the therapeutic potential of interleukin-6 receptor blockade in autoimmune diseases using drug target mendelian randomization.

Jiaxin Li, Yalin Liu, Zheng Xiao, Chenyang Zang, Peihong Li, Bo Xiao, Luo Zhou

Abstract read
PubMed Publisher
In one paragraph

Article in Immunogenetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiaxin Li *Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yalin Liu *Department of Clinical Nutrition, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Zheng XiaoDepartment of Pathology, First Hospital of Changsha, Changsha, Hunan, China.
Chenyang ZangDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Peihong LiDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Bo XiaoDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Luo ZhouDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China. zhouluo@csu.edu.cn.ORCID http://orcid.org/0000-0002-9250-151X

Funding

National Natural Science Foundation of China 81601139Natural Science Foundation of Hunan Province 2024JJ5576
6 · The paper itself

Abstract

The blockade of the interleukin 6 receptor (IL-6R) demonstrates significant potential in various autoimmune diseases (ADs); however, the underlying therapeutic efficacy associated with this approach remains elusive. We conducted a comprehensive Mendelian randomization (MR) analysis based on large-scale genome-wide association studies to investigate the causal relationships between genetically proxied IL-6R blockade weighted by serum C-reactive protein levels and eighteen common ADs. Rheumatoid arthritis, COVID-19 infection, and COVID-19 critical illness were utilized as positive controls. The inverse-variance weighted (IVW) method was utilized as the primary analytical tool, while genetic colocalization analysis was conducted to further substantiate the causalities. Genetically proxied IL-6R blockade exhibited causally protective effects on all positive control diseases. After Bonferroni correction to IVW estimates, genetically proxied IL-6R blockade may significantly increase the risk of asthma (OR=1.031, P=2.15×10

Indexed as

Autoimmune DiseasesGenome-Wide Association StudyMendelian Randomization AnalysisReceptors, Interleukin-6Arthritis, RheumatoidAsthmaCOVID-19C-Reactive ProteinHumansPolymorphism, Single NucleotideC-Reactive ProteinIL6R protein, humanReceptors, Interleukin-6Autoimmune diseasesCausal associationC-reactive proteinInterleukin 6 receptor blockadeMendelian randomization

Identifiers

PMID39589413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.